Erin Adler, DO
Hematology & Oncology · Augusta, MENPI 1053706069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,466 of the $5,209 with a category attached, or 85.7%. It is spread thinly across 32 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,905 and has fallen 78.8% since, to $405 in 2025.
Across 107 payments — averaging $48.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$970
- Daiichi Sankyo Inc.$525
- Incyte Corporation$352
- Pfizer$325
- Exelixis Inc.$318
- Sanofi$267
- plus $2K from 26 others
What the payments were for
- Consulting fees$52510%
- Food & beverage$4,46686%
- Education$2174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $970 |
| Daiichi Sankyo Inc. | 1 | $525 |
| Incyte Corporation | 10 | $352 |
| Pfizer | 9 | $325 |
| Exelixis Inc. | 5 | $318 |
| Sanofi | 4 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $206 |
| Astellas Pharma US Inc | 2 | $196 |
| Merck | 6 | $192 |
| Genentech USA, Inc. | 3 | $171 |
| Beigene USA, Inc. | 3 | $157 |
| Clovis Oncology, Inc. | 2 | $132 |
| Bayer | 2 | $127 |
| Seagen Inc. | 2 | $127 |
| Eisai Inc. | 1 | $125 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $115 |
| Pharmaessentia USA Corporation | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 1 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Novartis | 4 | $94 |
| Gilead | 4 | $91 |
| Amgen | 4 | $84 |
| Bristol Myers Squibb | 4 | $74 |
| Lilly USA, LLC | 2 | $42 |
| Morphosys, US Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $35 |
| AbbVie | 1 | $28 |
| GSK | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $18 |
| Genmab U.S., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,209 in reported general payments places this provider in the 75th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 11 | $261,595 |
| Lenalidomide | 11 | $166,771 |
| DopteletAvatrombopag Maleate | 17 | $165,638 |
| IbrancePalbociclib | 11 | $135,847 |
| Abiraterone Acetate | 18 | $63,387 |
| EliquisApixaban | 18 | $15,857 |
| XareltoRivaroxaban | 13 | $7,365 |
| Anastrozole | 110 | $2,520 |
| Hydroxyurea | 31 | $729 |
| Dexamethasone | 21 | $602 |
| Oxycodone Hcl | 22 | $569 |
| Tamoxifen Citrate | 15 | $313 |
| Prochlorperazine Maleate | 16 | $254 |
| Gabapentin | 12 | $75 |
| Prednisone | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $318 | $261,59511 claims |
| PfizerIbrance, Eliquis | $325 | $151,70429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Augusta
- Ambreen IjazAugusta$18K
- David AdlerAugusta$4K
- Sariah LiuAugusta$876
- Lindsey HathawayAugusta$786
- Neil MajithiaAugusta$330
- Abby ThrowerAugusta$24
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Helen RyanKennebunk$83K
- Eleni NackosWestbrook$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.